X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (20) 20
imdc (17) 17
oncology (17) 17
humans (11) 11
metastasis (10) 10
female (9) 9
targeted therapy (9) 9
carcinoma, renal cell (8) 8
carcinoma, renal cell - drug therapy (8) 8
interferon-alpha (8) 8
kidney neoplasms - drug therapy (8) 8
male (8) 8
prognosis (8) 8
sunitinib (8) 8
survival (8) 8
antineoplastic agents - therapeutic use (7) 7
everolimus (7) 7
retrospective studies (7) 7
treatment outcome (7) 7
urology & nephrology (7) 7
cancer (6) 6
care and treatment (6) 6
kidney cancer (6) 6
metastatic renal cell carcinoma (6) 6
middle aged (6) 6
renal cell carcinoma (6) 6
sorafenib (6) 6
aged (5) 5
analysis (5) 5
kidney neoplasms - pathology (5) 5
animals (4) 4
clear cell-type renal cell carcinoma (4) 4
dendritic cells (4) 4
metastases (4) 4
mice (4) 4
model (4) 4
mskcc (4) 4
neoplasm metastasis (4) 4
pazopanib (4) 4
prognostic model (4) 4
urology (4) 4
abridged index medicus (3) 3
antineoplastic agents (3) 3
antineoplastic agents - administration & dosage (3) 3
antineoplastic agents - adverse effects (3) 3
carcinoma, renal cell - pathology (3) 3
databases, factual (3) 3
dendritic cells - immunology (3) 3
dendritic cells - metabolism (3) 3
efficacy (3) 3
kaplan-meier estimate (3) 3
molecular targeted therapy (3) 3
nivolumab (3) 3
outcome (3) 3
patient outcomes (3) 3
patients (3) 3
renal-cell carcinoma (3) 3
risk factors (3) 3
survival analysis (3) 3
therapy (3) 3
trial (3) 3
validation (3) 3
activation (2) 2
aged, 80 and over (2) 2
antimitotic agents (2) 2
apoptosis (2) 2
article (2) 2
cancer research (2) 2
carcinoma, renal cell - mortality (2) 2
carcinoma, renal cell - secondary (2) 2
carcinoma, renal cell - therapy (2) 2
cell biology (2) 2
chemical and pharmacologic phenomena (2) 2
clinical trials (2) 2
cytokines (2) 2
cytoreductive nephrectomy (2) 2
database consortium (2) 2
databases (2) 2
expression (2) 2
female genital diseases and pregnancy complications (2) 2
gene expression regulation (2) 2
graft rejection - immunology (2) 2
hematology (2) 2
hypertension (2) 2
il-23 (2) 2
imdc risk groups (2) 2
imdc risk model (2) 2
immune checkpoint (2) 2
immunology (2) 2
immunotherapy (2) 2
indoles - administration & dosage (2) 2
international metastatic renal cell carcinoma database consortium (2) 2
ipilimumab (2) 2
japan (2) 2
kidney neoplasms - mortality (2) 2
kidney neoplasms - therapy (2) 2
medical prognosis (2) 2
medicine & public health (2) 2
metastatic (2) 2
mice, inbred c57bl (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of geriatric oncology, 08/2019
Journal Article
European Journal of Cancer, ISSN 0959-8049, 05/2018, Volume 94, pp. 115 - 125
Journal Article
Cancer, ISSN 0008-543X, 08/2013, Volume 119, Issue 16, pp. 2999 - 3006
Journal Article
Urologic Oncology: Seminars and Original Investigations, ISSN 1078-1439, 12/2018, Volume 36, Issue 12, pp. 526.e13 - 526.e18
Despite important results achieved for metastatic renal cell carcinoma, some patients could benefit from local treatments or an initial active surveillance... 
Tumor burden | IMDC | Number of metastatic sites | Active surveillance | Prognosis | mRCC | THERAPY | EVEROLIMUS | ONCOLOGY | UROLOGY & NEPHROLOGY | Databases | Carcinoma, Renal cell | Metastasis | Physicians | Analysis | Index Medicus
Journal Article
Onkourologiâ, ISSN 1726-9776, 04/2019, Volume 15, Issue 1, pp. 125 - 130
Until now selection of the 1st line therapy for advanced clear-cell renal cell carcinoma was determined by patients distribution into favorable/ intermediate... 
nivolumab | IMDC intermediate and poor prognosis | renal-cell carcinoma | ipilimumab | 1st line
Journal Article
by Chen and Hernandez-Meza and Agrawal and Zhang and Xie and Gong and Hoerner and Srinivas and Oermann and Fan
Cancers, ISSN 2072-6694, 07/2019, Volume 11, Issue 7, p. 1000
With 15 drugs currently approved for the treatment of metastatic renal cell carcinoma (mRCC) and even more combination regimens with immunotherapy on the... 
kidney cancer | RCC | systemic treatment | immunotherapy | IMDC criteria | metastatic renal cell carcinoma | therapy sequencing | favorable-, poor-, and intermediate-risk prognosis RCC | targeted kinase inhibitors
Journal Article
Clinical Genitourinary Cancer, ISSN 1558-7673, 02/2018, Volume 16, Issue 1, pp. 13 - 20.e3
Given limited prospective clinical trial data of poor-risk patients with metastatic renal-cell carcinoma, we sought to provide a comprehensive analysis of this... 
IMDC risk groups | Prognosis | Targeted therapy | MSKCC risk groups | Risk stratification | SURVIVAL | CYTOKINES | PROGNOSTIC-FACTORS | EVEROLIMUS | PAZOPANIB | VALIDATION | MODEL | CANCER | ONCOLOGY | TEMSIROLIMUS | UROLOGY & NEPHROLOGY
Journal Article
Journal Article
Cancer, ISSN 0008-543X, 02/2016, Volume 122, Issue 3, pp. 411 - 419
Toxicities associated with vascular endothelial growth factor–targeted therapies can often compromise clinical benefit in patients with metastatic renal cell... 
International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) | toxicity | renal cell carcinoma | risk factors | treatment discontinuation | model | VEGF‐targeted therapies | VEGF-targeted therapies | SAFETY | OLDER-ADULTS | PHASE-III | SORAFENIB | CANCER | INTERFERON-ALPHA | ANGIOGENESIS INHIBITOR THERAPIES | ONCOLOGY | TREATMENT PATTERNS | SUNITINIB | CLINICAL-PRACTICE | Predictive Value of Tests | Humans | Middle Aged | Male | Fatigue - chemically induced | Kidney Neoplasms - metabolism | Antineoplastic Agents - administration & dosage | Hand-Foot Syndrome - etiology | Indazoles - administration & dosage | Indoles - administration & dosage | Kidney Neoplasms - blood | Pyrroles - administration & dosage | Aged, 80 and over | Pyrroles - adverse effects | Bevacizumab - administration & dosage | Risk Assessment | Imidazoles - adverse effects | Risk Factors | Niacinamide - adverse effects | Mucositis - chemically induced | Carcinoma, Renal Cell - metabolism | Indoles - adverse effects | Indazoles - adverse effects | Sulfonamides - administration & dosage | Niacinamide - analogs & derivatives | Bevacizumab - adverse effects | Imidazoles - administration & dosage | Diarrhea - chemically induced | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Female | Retrospective Studies | Vascular Endothelial Growth Factor A - drug effects | Carcinoma, Renal Cell - drug therapy | Molecular Targeted Therapy - methods | Databases, Factual | Molecular Targeted Therapy - adverse effects | Carcinoma, Renal Cell - blood | Drug Administration Schedule | Pyrimidines - administration & dosage | Kaplan-Meier Estimate | Models, Statistical | Niacinamide - administration & dosage | Phenylurea Compounds - administration & dosage | Carcinoma, Renal Cell - secondary | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Kidney Neoplasms - pathology | Aged | Kidney Neoplasms - drug therapy | Care and treatment | Dosage and administration | Carcinoma, Renal cell | Diagnosis | Vascular endothelial growth factor | Index Medicus | Abridged Index Medicus
Journal Article
Stem Cells and Development, ISSN 1547-3287, 04/2018, Volume 27, Issue 8, pp. 556 - 565
Mesenchymal stem cells (MSCs) have a superior immunomodulatory capacity compared to other cells of the immune system, and they hold great promise for treating... 
Original Research Reports | mesenchymal stem cell | IRF8 | imDC | Notch signaling | MEDICINE, RESEARCH & EXPERIMENTAL | ACTIVATION | INDUCE | MACROPHAGES | SUPPRESSION | CELL & TISSUE ENGINEERING | TRANSPLANTATION | OCCURS | GENERATION | HEMATOLOGY | EXPRESSION | Polycomb Repressive Complex 2 - genetics | Receptors, Notch - metabolism | Coculture Techniques | Antigens, Ly - genetics | Interferon Regulatory Factors - metabolism | Receptors, Notch - genetics | Proto-Oncogene Proteins c-kit - metabolism | Mesenchymal Stem Cells - cytology | Mesenchymal Stem Cells - drug effects | Antigens, Ly - metabolism | Bone Marrow Cells - drug effects | Dendritic Cells - drug effects | Proto-Oncogene Proteins c-kit - genetics | Cell Differentiation | Membrane Proteins - metabolism | Immunoglobulin J Recombination Signal Sequence-Binding Protein - genetics | Mesenchymal Stem Cells - metabolism | Dendritic Cells - metabolism | Immunoglobulin J Recombination Signal Sequence-Binding Protein - metabolism | Promoter Regions, Genetic | Signal Transduction | Bone Marrow Cells - cytology | Membrane Proteins - genetics | Mice, Inbred C57BL | Gene Expression Regulation | Interferon Regulatory Factors - genetics | Toll-Like Receptor 4 - genetics | Toll-Like Receptor 4 - metabolism | Proteins - genetics | Animals | Histones - genetics | Proteins - metabolism | Lipopolysaccharides - pharmacology | Dendritic Cells - cytology | Mice | Mice, Inbred BALB C | Histones - metabolism | Polycomb Repressive Complex 2 - metabolism | Bone Marrow Cells - metabolism | Index Medicus
Journal Article
Journal Article